http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update
-
BioLineRx (BLRX) Announces Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
-
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
-
BioLineRx to Present at the 2019 Biotech Showcase
-
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
-
BioLineRx (BLRX) Receives FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
-
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
-
BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update
-
BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
-
BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
-
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
-
BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
-
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
-
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
-
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
-
BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients
-
BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
-
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
-
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
-
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
-
BioLineRx (BLRX) Announces Notice of Allowance From USPTO for Patent Covering AGI-134
-
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
-
BioLineRx Reports Year End 2017 Financial Results
-
BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
-
BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
-
BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
-
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
-
BioLineRx (BLRX) Announces Positive Overall Survival Results From L-T Follow-up of Phase 2a Trial in r/r AML
-
BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
-
BioLineRx Reports Third Quarter 2017 Financial Results
-
BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium
-
BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York
-
BioLineRx to Report Third Quarter 2017 Results on November 21, 2017
-
BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment
-
BioLineRx (BLRX) Says Genentech Commenced Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
-
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
-
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy Collaboration
-
BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization
-
BioLineRx Reports Second Quarter 2017 Financial Results
-
BioLineRx Announces Additional Investment From BVF Partners L.P.
-
BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
-
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
-
BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors
-
BioLineRx Reports First Quarter 2017 Financial Results
-
BioLineRx (BLRX) Files BL-8040 Phase 1b Trial Regulatory Submission in Combo with atezolizumab in AML
-
BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
-
BioLineRx to Report First Quarter 2017 Results on May 25, 2017
-
BioLineRx (BLRX) Initiate Phase 3 Study with BL-8040 Following Successful Meeting with FDA
-
BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
-
BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
